TY - JOUR
T1 - Controversies in optimal anemia management
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
AU - Conference Participants
AU - Babitt, Jodie L.
AU - Eisenga, Michele F.
AU - Haase, Volker H.
AU - Kshirsagar, Abhijit V.
AU - Levin, Adeera
AU - Locatelli, Francesco
AU - Małyszko, Jolanta
AU - Swinkels, Dorine W.
AU - Tarng, Der Cherng
AU - Cheung, Michael
AU - Jadoul, Michel
AU - Winkelmayer, Wolfgang C.
AU - Drüeke, Tilman B.
AU - Abu-Alfa, Ali K.
AU - Afsar, Baris
AU - Pai, Amy Barton
AU - Besarab, Anatole
AU - Moore, Geraldine Biddle
AU - Casadevall, Nicole
AU - Cases, Aleix
AU - de Francisco, Angel
AU - Eckardt, Kai Uwe
AU - Fishbane, Steven
AU - Fried, Linda F.
AU - Ganz, Tomas
AU - Ginzburg, Yelena Z.
AU - Gómez, Rafael
AU - Goodnough, Lawrence T.
AU - Hamano, Takayuki
AU - Hanudel, Mark R.
AU - Hao, Chuan Ming
AU - Iseki, Kunitoshi
AU - Ix, Joachim H.
AU - Johansen, Kirsten L.
AU - Ketteler, Markus
AU - Kovesdy, Csaba P.
AU - Leaf, David E.
AU - Macdougall, Iain C.
AU - Massy, Ziad A.
AU - McMahon, Lawrence P.
AU - Minutolo, Roberto
AU - Nakanishi, Takeshi
AU - Nemeth, Elizabeta
AU - Obrador, Gregorio T.
AU - Parfrey, Patrick S.
AU - Park, Hyeong Cheon
AU - Pecoits-Filho, Roberto
AU - Robinson, Bruce M.
AU - Roger, Simon D.
AU - Shah, Yatrik M.
N1 - Publisher Copyright:
© 2021 International Society of Nephrology
PY - 2021/6
Y1 - 2021/6
N2 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.
AB - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.
KW - anemia
KW - chronic kidney disease
KW - dialysis
KW - erythropoiesis stimulating agents
KW - erythropoietin
KW - hepcidin
KW - hypoxia-inducible factor-prolyl hydroxylase inhibitor
KW - iron
KW - iron deficiency
UR - http://www.scopus.com/inward/record.url?scp=85105717237&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2021.03.020
DO - 10.1016/j.kint.2021.03.020
M3 - Article
C2 - 33839163
AN - SCOPUS:85105717237
SN - 0085-2538
VL - 99
SP - 1280
EP - 1295
JO - Kidney International
JF - Kidney International
IS - 6
ER -